Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma.

Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C

The Journal of urology1 Apr 1999Cited by 210 (Europe PMC)

PMID10081873DOI10.1016/s0022-5347(01)61639-2PepBankPUB-10081873

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialSafety outcome
In men with prostatic carcinoma, lumbar BMD decreased nonsignificantly after 6 months of triptorelin.
In plain wordsIn men with prostate cancer, spine bone density decreased nonsignificantly after 6 months of triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLumbar BMD at month 6
Study
n = 9
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg every 4 weeks · intramuscular · 6 monthsAs given in this study (human).
Measurements
Lumbar BMD change
−3%
month 6 versus baseline
Source sentences
Summary
In comparison with month 0, the lumbar and femoral neck bone mineral density tended to decrease at month 6 (-3 and -2.7%, p = 0.31 and 0.17, respectively), at month 12 (-4.6 and -3.9%, p = 0.13 and 0.13) and at month 18 (-7.1 and -6.6%, p = 0.12 and 0.027).
2 context sentences(design, population, supporting numbers)
Summary · context
Bone mineral density and parameters of mineral metabolism were evaluated in 12 patients with stage C prostatic carcinoma before and after 6, 12 and 18 months of treatment with 3.75 mg. triptorelin intramuscularly every 4 weeks.
Summary · context
Of the 12 patients 9 were evaluated after 6, 7 after 12 and 6 after 18 months of therapy.
Report a problemFND-1008187301
02HumanNon-randomized trialSafety outcome
In men with prostatic carcinoma, femoral neck BMD decreased nonsignificantly after 6 months of triptorelin.
In plain wordsIn men with prostate cancer, femoral neck bone density decreased nonsignificantly after 6 months of triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFemoral neck BMD at month 6
Study
n = 9
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg every 4 weeks · intramuscular · 6 monthsAs given in this study (human).
Measurements
Femoral neck BMD change
−2.7%
month 6 versus baseline
Source sentences
Summary
In comparison with month 0, the lumbar and femoral neck bone mineral density tended to decrease at month 6 (-3 and -2.7%, p = 0.31 and 0.17, respectively), at month 12 (-4.6 and -3.9%, p = 0.13 and 0.13) and at month 18 (-7.1 and -6.6%, p = 0.12 and 0.027).
2 context sentences(design, population, supporting numbers)
Summary · context
Bone mineral density and parameters of mineral metabolism were evaluated in 12 patients with stage C prostatic carcinoma before and after 6, 12 and 18 months of treatment with 3.75 mg. triptorelin intramuscularly every 4 weeks.
Summary · context
Of the 12 patients 9 were evaluated after 6, 7 after 12 and 6 after 18 months of therapy.
Report a problemFND-1008187302
03HumanNon-randomized trialSafety outcome
In men with prostatic carcinoma, lumbar BMD decreased nonsignificantly after 12 months of triptorelin.
In plain wordsIn men with prostate cancer, spine bone density decreased nonsignificantly after 12 months of triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLumbar BMD at month 12
Study
n = 7
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg every 4 weeks · intramuscular · 12 monthsAs given in this study (human).
Measurements
Lumbar BMD change
−4.6%
month 12 versus baseline
Source sentences
Summary
In comparison with month 0, the lumbar and femoral neck bone mineral density tended to decrease at month 6 (-3 and -2.7%, p = 0.31 and 0.17, respectively), at month 12 (-4.6 and -3.9%, p = 0.13 and 0.13) and at month 18 (-7.1 and -6.6%, p = 0.12 and 0.027).
2 context sentences(design, population, supporting numbers)
Summary · context
Bone mineral density and parameters of mineral metabolism were evaluated in 12 patients with stage C prostatic carcinoma before and after 6, 12 and 18 months of treatment with 3.75 mg. triptorelin intramuscularly every 4 weeks.
Summary · context
Of the 12 patients 9 were evaluated after 6, 7 after 12 and 6 after 18 months of therapy.
Report a problemFND-1008187303
04HumanNon-randomized trialSafety outcome
In men with prostatic carcinoma, femoral neck BMD decreased nonsignificantly after 12 months of triptorelin.
In plain wordsIn men with prostate cancer, femoral neck bone density decreased nonsignificantly after 12 months of triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFemoral neck BMD at month 12
Study
n = 7
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg every 4 weeks · intramuscular · 12 monthsAs given in this study (human).
Measurements
Femoral neck BMD change
−3.9%
month 12 versus baseline
Source sentences
Summary
In comparison with month 0, the lumbar and femoral neck bone mineral density tended to decrease at month 6 (-3 and -2.7%, p = 0.31 and 0.17, respectively), at month 12 (-4.6 and -3.9%, p = 0.13 and 0.13) and at month 18 (-7.1 and -6.6%, p = 0.12 and 0.027).
2 context sentences(design, population, supporting numbers)
Summary · context
Bone mineral density and parameters of mineral metabolism were evaluated in 12 patients with stage C prostatic carcinoma before and after 6, 12 and 18 months of treatment with 3.75 mg. triptorelin intramuscularly every 4 weeks.
Summary · context
Of the 12 patients 9 were evaluated after 6, 7 after 12 and 6 after 18 months of therapy.
Report a problemFND-1008187304
05HumanNon-randomized trialSafety outcome
In men with prostatic carcinoma, lumbar BMD decreased nonsignificantly after 18 months of triptorelin.
In plain wordsIn men with prostate cancer, spine bone density decreased nonsignificantly after 18 months of triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLumbar BMD at month 18
Study
n = 6
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg every 4 weeks · intramuscular · 18 monthsAs given in this study (human).
Measurements
Lumbar BMD change
−7.1%
month 18 versus baseline
Source sentences
Summary
In comparison with month 0, the lumbar and femoral neck bone mineral density tended to decrease at month 6 (-3 and -2.7%, p = 0.31 and 0.17, respectively), at month 12 (-4.6 and -3.9%, p = 0.13 and 0.13) and at month 18 (-7.1 and -6.6%, p = 0.12 and 0.027).
2 context sentences(design, population, supporting numbers)
Summary · context
Bone mineral density and parameters of mineral metabolism were evaluated in 12 patients with stage C prostatic carcinoma before and after 6, 12 and 18 months of treatment with 3.75 mg. triptorelin intramuscularly every 4 weeks.
Summary · context
Of the 12 patients 9 were evaluated after 6, 7 after 12 and 6 after 18 months of therapy.
Report a problemFND-1008187305
06HumanNon-randomized trialSafety outcome
In men with prostatic carcinoma, femoral neck BMD decreased significantly after 18 months of triptorelin.
In plain wordsIn men with prostate cancer, femoral neck bone density decreased after 18 months of triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseFemoral neck BMD at month 18
Study
n = 6
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg every 4 weeks · intramuscular · 18 monthsAs given in this study (human).
Measurements
Femoral neck BMD change
−6.6%
month 18 versus baseline
Source sentences
Summary
In comparison with month 0, the lumbar and femoral neck bone mineral density tended to decrease at month 6 (-3 and -2.7%, p = 0.31 and 0.17, respectively), at month 12 (-4.6 and -3.9%, p = 0.13 and 0.13) and at month 18 (-7.1 and -6.6%, p = 0.12 and 0.027).
2 context sentences(design, population, supporting numbers)
Summary · context
Bone mineral density and parameters of mineral metabolism were evaluated in 12 patients with stage C prostatic carcinoma before and after 6, 12 and 18 months of treatment with 3.75 mg. triptorelin intramuscularly every 4 weeks.
Summary · context
Of the 12 patients 9 were evaluated after 6, 7 after 12 and 6 after 18 months of therapy.
Report a problemFND-1008187306
07HumanNon-randomized trialSafety outcome
In men with prostatic carcinoma, lumbar BMD was significantly lower at the last triptorelin evaluation than at baseline.
In plain wordsIn men with prostate cancer, spine bone density was lower at the last triptorelin evaluation than at baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseLumbar BMD at last evaluation
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg every 4 weeks · intramuscularAs given in this study (human).
Source sentences
Summary
A second analysis revealed that the lumbar and femoral neck bone mineral density was significantly decreased on the last evaluation compared to month 0 (p = 0.05 and 0.028, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Bone mineral density and parameters of mineral metabolism were evaluated in 12 patients with stage C prostatic carcinoma before and after 6, 12 and 18 months of treatment with 3.75 mg. triptorelin intramuscularly every 4 weeks.
Report a problemFND-1008187307
08HumanNon-randomized trialSafety outcome
In men with prostatic carcinoma, femoral neck BMD was significantly lower at the last triptorelin evaluation than at baseline.
In plain wordsIn men with prostate cancer, femoral neck bone density was lower at the last triptorelin evaluation than at baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseFemoral neck BMD at last evaluation
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg every 4 weeks · intramuscularAs given in this study (human).
Source sentences
Summary
A second analysis revealed that the lumbar and femoral neck bone mineral density was significantly decreased on the last evaluation compared to month 0 (p = 0.05 and 0.028, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Bone mineral density and parameters of mineral metabolism were evaluated in 12 patients with stage C prostatic carcinoma before and after 6, 12 and 18 months of treatment with 3.75 mg. triptorelin intramuscularly every 4 weeks.
Report a problemFND-1008187308
09HumanNon-randomized trialSafety outcome
In men with prostatic carcinoma, serum osteocalcin increased during triptorelin treatment.
In plain wordsIn men with prostate cancer, osteocalcin increased during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseSerum osteocalcin
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
3.75 mg every 4 weeks · intramuscularAs given in this study (human).
Source sentences
Summary
The serum osteocalcin was increased during treatment, suggesting an accelerated bone turnover in men treated with Gn-RH agonists.
1 context sentence(design, population, supporting numbers)
Summary · context
Bone mineral density and parameters of mineral metabolism were evaluated in 12 patients with stage C prostatic carcinoma before and after 6, 12 and 18 months of treatment with 3.75 mg. triptorelin intramuscularly every 4 weeks.
Report a problemFND-1008187309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.